ArticleReproductive sciences (Thousand Oaks, Calif.)2025
From Dominant Assumptions to Recessive Trait: Rethinking BMP15 in Ovarian Dysfunction.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SIRT1 deacetylates PKM2 to constrain lactate production and protect against premature ovarian insufficiency.Life medicine · 2026Article
- Premature Ovarian Insufficiency and Diminished Ovarian Reserve: From Diagnosis to Current Management and Treatment.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 1% of women experience premature ovarian insufficiency (POI) before the age of 40. Genetic factors play a significant role in the development of POI. The BMP15 gene is one of the first genes involved in POI. However, the pathogenicity and the penetrance of BMP15 variants still remain unclear. A cohort of 500 patients with POI/DOR (diminished ovarian reserve) underwent next generation sequencing of the entire coding region of the BMP15 gene. The frequency of each identified BMP15 variant was then compared with that of the general population, taking into account the ethnicity of each individual. Screening of the entire coding region of the BMP15 gene allowed us the identification of 11 different variants, including one pathogenic non-sense variant. A total of 54 patients with POI (10.8%) carried out at least one BMP15 variant. With regard to missense variants, we observed a significant overrepresentation of two missense variants (2/10 missense variants) in our 500 POI patients when compared to the general or specific ethnic subgroups. Of interest is the identification of one homozygous POI subject with a loss-of-function variant. The results of the segregation analysis indicated that this variant was inherited by the healthy mother (menarche at 16 years of age, and physiological menopause at 53 years of age) and by the father. This epidemiological study suggests that the majority of heterozygous missense variants could be considered as benign variants, while the homozygous loss-of-function variant could be considered as pathogenic variant. Several missense variants should be considered as variants of uncertain significance, conferring a moderate risk with probable partial and very low penetrance and/or expressivity. However, it should be noted that these variants are only deleterious in the compound heterozygous or homozygous status.
Indexed as
Identifiers
40274730What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.